STOCK TITAN

COVALON TECHS LTD - CVALF STOCK NEWS

Welcome to our dedicated page for COVALON TECHS news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on COVALON TECHS stock.

Covalon Technologies Ltd. is a global leader in researching, developing, and commercializing healthcare technologies that save lives worldwide. With patented products and services, Covalon addresses medical device companies, healthcare providers, and individual consumers' advanced healthcare needs. Specializing in wound care, tissue repair, infection control, disease management, medical device coatings, and biocompatibility, Covalon's technologies prevent, detect, and manage various medical conditions.

Rhea-AI Summary

Covalon Technologies Ltd. (OTCQX: CVALF) will participate in the NEO Conference for Neonatology in Las Vegas from February 22 to 24, 2023. This marks the company's first appearance at the event, aimed at enhancing neonatal care through innovative solutions. Covalon's products focus on preventing infections in infants, significantly aiding top pediatric hospitals in the U.S. The company offers solutions such as VALGuard and IV Clear. With a commitment to improving patient outcomes, Covalon emphasizes compassionate care, which is vital for vulnerable neonates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Covalon Technologies Ltd. (TSXV: COV, OTCQX: CVALF) will release its Q1 Fiscal 2023 financial results on February 23, 2023, before markets open. A conference call and webcast are scheduled for the same day at 9:00 am EST. Participants can join the call by dialing North American Toll-Free: 1-888-664-6392 or through a provided link for a callback option. The call will allow participants to engage in a Q&A session with management. Financial statements will be available on SEDAR and Covalon's website. The company focuses on advanced medical technologies aimed at improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.16%
Tags
-
Rhea-AI Summary

Covalon Technologies Ltd. (CVALF) announced its fiscal 2022 Q4 and year-end results, reporting a 7% decline in revenue to $18.1M from $19.6M in the prior year. The company experienced a net loss of $9.7M, or $0.38 per share, compared to a profit of $23.5M in fiscal 2021. Operating expenses surged to $16.6M, driven by investments in marketing and leadership. Despite challenges, Covalon is optimistic about future revenue growth, especially in the U.S. market, where it secured its products in over 70 hospitals. The management commits to enhancing margins and profitability through operational improvements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.38%
Tags
Rhea-AI Summary

Covalon Technologies Ltd. (TSXV: COV, OTCQX: CVALF) will announce its Q4 and Fiscal 2022 financial results on January 25, 2023, after market close. A conference call is scheduled for January 26, 2023, at 9:00 AM EST, to discuss these results. Participants can join the call via telephone or through a live webcast. A recording will be available post-call until February 9, 2023. Financial statements will be accessible through SEDAR and the company's website. Covalon specializes in advanced medical technologies that enhance patient outcomes in various medical fields.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
-
Rhea-AI Summary

Covalon Technologies Ltd. (OTCQX:CVALF) will present at the Planet MicroCap Investor Showcase: VIRTUAL 2022 on December 7, 2022, at 8:30 AM EST. CEO Brian Pedlar will lead the session and answer questions afterward. Covalon specializes in patented medical technologies that enhance patient care by reducing infection risks and improving healing processes. Interested investors can access the live presentation via webcast and can schedule 1-on-1 meetings. More details are available through the provided links.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Covalon Technologies Ltd. has launched a new campaign titled 'CLABSI Conscious' to combat the rising rates of Central Line Associated Blood Stream Infections (CLABSIs) in U.S. hospitals, particularly among pediatric patients. This initiative comes in response to a staggering 47% increase in CLABSI rates reported by the CDC. The campaign focuses on using advanced technology to enhance infection prevention practices, alongside a new blog and renewed social media outreach to raise awareness about infection risks. An expert-led webinar is scheduled for November 9, 2022, to discuss solutions for reducing CLABSI rates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Covalon Technologies Ltd. presented its advanced wound care product, ColActive Plus Powder, at the Symposium on Advanced Wound Care held from October 13 to 16, 2022, in Las Vegas. A case study by Dr. Alton Johnson Jr. at the University of Michigan showcased its effectiveness in treating chronic wounds. Notably, an 83-year-old patient with non-healing post-amputation wounds healed within 28 days using this product. This success highlights its potential to significantly impact patient care for those with chronic wounds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Covalon Technologies Ltd. (CVALF) announced its participation in the ANCC Magnet Conference in Philadelphia from October 13 to 15, 2022. The company, known for its advanced medical technologies, will showcase its innovative infection prevention solutions, including VALGuard, which reduces catheter-related infection risks. CEO Brian Pedlar emphasized the importance of infection-free environments for hospitalized children. Attendees can visit Covalon at booth 1557 to learn more about their products aimed at improving patient outcomes and caregiver experiences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Covalon Technologies Ltd. will participate in the 12th International Pediatric Intestinal Failure and Rehabilitation Symposium in Toronto from September 30 to October 2, 2022. This event unites healthcare professionals focused on the care of children suffering from intestinal failure. The company aims to showcase its innovative products that offer enhanced infection protection for patients, particularly those needing long-term intravenous access. Covalon emphasizes that CLABSIs have surged during the pandemic, highlighting the urgency for effective infection prevention protocols.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Covalon Technologies Ltd. (OTCQX: CVALF) will co-sponsor the Association for Vascular Access (AVA) Annual Scientific Meeting from September 30 to October 2, 2022, at the Minneapolis Convention Center. The company aims to showcase its advanced infection prevention solutions, including the FDA-listed VALGuard and IV Clear products. VALGuard protects catheter hubs from contamination, while IV Clear serves as a dual-antimicrobial dressing. CEO Brian Pedlar emphasizes the importance of innovative solutions in improving patient care and minimizing infection risks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none

FAQ

What is the current stock price of COVALON TECHS (CVALF)?

The current stock price of COVALON TECHS (CVALF) is $2.65 as of November 22, 2024.

What is the market cap of COVALON TECHS (CVALF)?

The market cap of COVALON TECHS (CVALF) is approximately 78.9M.

What does Covalon Technologies Ltd. specialize in?

Covalon specializes in researching, developing, and commercializing healthcare technologies for wound care, tissue repair, infection control, disease management, medical device coatings, and biocompatibility.

Which sectors does Covalon cater to?

Covalon caters to medical device companies, healthcare providers, and individual consumers globally.

What is unique about Covalon's patented technologies?

Covalon's patented technologies are designed to prevent, detect, and manage various medical conditions, setting them apart as a global leader in healthcare technology.

Where can I find more information about Covalon Technologies Ltd.?

For more information about Covalon Technologies Ltd., visit their official website at www.covalon.com.

How does Covalon Technologies Ltd. contribute to the healthcare industry?

Covalon contributes to the healthcare industry by offering innovative solutions that address advanced healthcare needs and help save lives around the world.

What is the mission of Covalon Technologies Ltd.?

Covalon's mission is to research, develop, and commercialize healthcare technologies that make a significant impact in preventing, detecting, and managing medical conditions.

Why is Covalon Technologies Ltd. considered a global leader in healthcare technologies?

Covalon is considered a global leader due to its focus on innovation, patented technologies, and commitment to addressing critical healthcare needs worldwide.

How does Covalon Technologies Ltd. contribute to wound care and infection control?

Covalon specializes in technologies that are crucial for wound care, infection control, and other specialty areas to improve patient outcomes and healthcare standards.

What sets Covalon Technologies Ltd. apart from other healthcare technology companies?

Covalon's focus on advanced medical solutions, patented technologies, and global reach distinguish it from other healthcare technology companies in the industry.

What are the core values of Covalon Technologies Ltd.?

Covalon values innovation, quality, patient care, and global impact in its mission to provide cutting-edge healthcare technologies to improve lives worldwide.

COVALON TECHS LTD

OTC:CVALF

CVALF Rankings

CVALF Stock Data

78.91M
11.71M
48.7%
Biotechnology
Healthcare
Link
United States of America
Mississauga